Joint Filer Information
| Names: | Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P. |
| | |
| Address: | 345 Park Avenue South, 12th Floor New York, NY 10010 |
| | |
| Designated Filer: | James E. Flynn |
| | |
| Issuer and Ticker Symbol: | ARS Pharmaceuticals, Inc. [SPRY] |
| | |
| Date of Event Requiring Statement: | November 8, 2022 |
The undersigned, Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P., are jointly filing the attached Initial Statement of Beneficial Ownership on Form 3 with James E. Flynn with respect to the beneficial ownership of securities of ARS Pharmaceuticals, Inc.
Signatures:
DEERFIELD MGMT III, L.P. By: J.E. Flynn Capital III, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact | DEERFIELD MGMT IV, L.P. By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact |
| | |
DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn Management LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact | DEERFIELD PRIVATE DESIGN FUND IV, L.P. By: Deerfield Mgmt IV, L.P., General Partner By: J.E. Flynn Capital IV, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact |
| | |
DEERFIELD PRIVATE DESIGN FUND III, L.P. By: Deerfield Mgmt III, L.P., General Partner By: J.E. Flynn Capital III, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact | |
